These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 16181099)

  • 21. Reduced postsynaptic GABAA receptor number and enhanced gaboxadol induced change in holding currents in Purkinje cells of the dystrophin-deficient mdx mouse.
    Kueh SL; Dempster J; Head SI; Morley JW
    Neurobiol Dis; 2011 Sep; 43(3):558-64. PubMed ID: 21601636
    [TBL] [Abstract][Full Text] [Related]  

  • 22. "Of Mice and Measures": A Project to Improve How We Advance Duchenne Muscular Dystrophy Therapies to the Clinic.
    Gordish-Dressman H; Willmann R; Dalle Pazze L; Kreibich A; van Putten M; Heydemann A; Bogdanik L; Lutz C; Davies K; Demonbreun AR; Duan D; Elsey D; Fukada SI; Girgenrath M; Patrick Gonzalez J; Grounds MD; Nichols A; Partridge T; Passini M; Sanarica F; Schnell FJ; Wells DJ; Yokota T; Young CS; Zhong Z; Spurney C; Spencer M; De Luca A; Nagaraju K; Aartsma-Rus A
    J Neuromuscul Dis; 2018; 5(4):407-417. PubMed ID: 30198876
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Treatment with human immunoglobulin G improves the early disease course in a mouse model of Duchenne muscular dystrophy.
    Zschüntzsch J; Zhang Y; Klinker F; Makosch G; Klinge L; Malzahn D; Brinkmeier H; Liebetanz D; Schmidt J
    J Neurochem; 2016 Jan; 136(2):351-62. PubMed ID: 26230042
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effect of a long-term treatment with metformin in dystrophic mdx mice: A reconsideration of its potential clinical interest in Duchenne muscular dystrophy.
    Mantuano P; Sanarica F; Conte E; Morgese MG; Capogrosso RF; Cozzoli A; Fonzino A; Quaranta A; Rolland JF; De Bellis M; Camerino GM; Trabace L; De Luca A
    Biochem Pharmacol; 2018 Aug; 154():89-103. PubMed ID: 29684379
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Increased calcium in neurons in the cerebral cortex and cerebellum is not associated with cell loss in the mdx mouse model of Duchenne muscular dystrophy.
    Tuckett E; Gosetti T; Hayes A; Rybalka E; Verghese E
    Neuroreport; 2015 Sep; 26(13):785-90. PubMed ID: 26177336
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Myelination is delayed during postnatal brain development in the mdx mouse model of Duchenne muscular dystrophy.
    Aranmolate A; Tse N; Colognato H
    BMC Neurosci; 2017 Aug; 18(1):63. PubMed ID: 28806929
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cognitive dysfunction in the dystrophin-deficient mouse model of Duchenne muscular dystrophy: A reappraisal from sensory to executive processes.
    Chaussenot R; Edeline JM; Le Bec B; El Massioui N; Laroche S; Vaillend C
    Neurobiol Learn Mem; 2015 Oct; 124():111-22. PubMed ID: 26190833
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pre-clinical evaluation of N-acetylcysteine reveals side effects in the mdx mouse model of Duchenne muscular dystrophy.
    Pinniger GJ; Terrill JR; Assan EB; Grounds MD; Arthur PG
    J Physiol; 2017 Dec; 595(23):7093-7107. PubMed ID: 28887840
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A mouse anti-myostatin antibody increases muscle mass and improves muscle strength and contractility in the mdx mouse model of Duchenne muscular dystrophy and its humanized equivalent, domagrozumab (PF-06252616), increases muscle volume in cynomolgus monkeys.
    St Andre M; Johnson M; Bansal PN; Wellen J; Robertson A; Opsahl A; Burch PM; Bialek P; Morris C; Owens J
    Skelet Muscle; 2017 Nov; 7(1):25. PubMed ID: 29121992
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cell surface and gene expression regulation molecules in dystrophinopathy: mdx vs. Duchenne.
    Fadic R
    Biol Res; 2005; 38(4):375-80. PubMed ID: 16579520
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Expression and localization of protein inhibitor of neuronal nitric oxide synthase in Duchenne muscular dystrophy.
    Guo Y; Petrof BJ; Hussain SN
    Muscle Nerve; 2001 Nov; 24(11):1468-75. PubMed ID: 11745948
    [TBL] [Abstract][Full Text] [Related]  

  • 32. T and B lymphocyte depletion has a marked effect on the fibrosis of dystrophic skeletal muscles in the scid/mdx mouse.
    Farini A; Meregalli M; Belicchi M; Battistelli M; Parolini D; D'Antona G; Gavina M; Ottoboni L; Constantin G; Bottinelli R; Torrente Y
    J Pathol; 2007 Oct; 213(2):229-38. PubMed ID: 17668421
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Protein-Anchoring Therapy of Biglycan for Mdx Mouse Model of Duchenne Muscular Dystrophy.
    Ito M; Ehara Y; Li J; Inada K; Ohno K
    Hum Gene Ther; 2017 May; 28(5):428-436. PubMed ID: 27485975
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Matrix metalloproteinase-2 ablation in dystrophin-deficient mdx muscles reduces angiogenesis resulting in impaired growth of regenerated muscle fibers.
    Miyazaki D; Nakamura A; Fukushima K; Yoshida K; Takeda S; Ikeda S
    Hum Mol Genet; 2011 May; 20(9):1787-99. PubMed ID: 21320869
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Enhanced expression of the alpha 7 beta 1 integrin reduces muscular dystrophy and restores viability in dystrophic mice.
    Burkin DJ; Wallace GQ; Nicol KJ; Kaufman DJ; Kaufman SJ
    J Cell Biol; 2001 Mar; 152(6):1207-18. PubMed ID: 11257121
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Zidovudine ameliorates pathology in the mouse model of Duchenne muscular dystrophy via P2RX7 purinoceptor antagonism.
    Al-Khalidi R; Panicucci C; Cox P; Chira N; Róg J; Young CNJ; McGeehan RE; Ambati K; Ambati J; Zabłocki K; Gazzerro E; Arkle S; Bruno C; Górecki DC
    Acta Neuropathol Commun; 2018 Apr; 6(1):27. PubMed ID: 29642926
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Angiogenic impairment of the vascular endothelium: a novel mechanism and potential therapeutic target in muscular dystrophy.
    Palladino M; Gatto I; Neri V; Straino S; Smith RC; Silver M; Gaetani E; Marcantoni M; Giarretta I; Stigliano E; Capogrossi M; Hlatky L; Landolfi R; Pola R
    Arterioscler Thromb Vasc Biol; 2013 Dec; 33(12):2867-76. PubMed ID: 24072696
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Respiratory Control in the mdx Mouse Model of Duchenne Muscular Dystrophy.
    Burns DP; Edge D; O'Malley D; O'Halloran KD
    Adv Exp Med Biol; 2015; 860():239-44. PubMed ID: 26303487
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Targeting RAGE as a potential therapeutic approach to Duchenne muscular dystrophy.
    Sagheddu R; Chiappalupi S; Salvadori L; Riuzzi F; Donato R; Sorci G
    Hum Mol Genet; 2018 Nov; 27(21):3734-3746. PubMed ID: 30085099
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The first exon duplication mouse model of Duchenne muscular dystrophy: A tool for therapeutic development.
    Vulin A; Wein N; Simmons TR; Rutherford AM; Findlay AR; Yurkoski JA; Kaminoh Y; Flanigan KM
    Neuromuscul Disord; 2015 Nov; 25(11):827-34. PubMed ID: 26365037
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.